Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / ADR
-
Shares outstanding
-
55,574,229
-
Total 13F shares
-
65,178,531
-
Share change
-
+1,401,972
-
Total reported value
-
$10,147,207,193
-
Put/Call ratio
-
150%
-
Price per share
-
$155.86
-
Number of holders
-
240
-
Value change
-
+$223,137,113
-
Number of buys
-
128
-
Number of sells
-
109
Institutional Holders of Ascendis Pharma A/S - ADR (ASND) as of Q1 2025
As of 31 Mar 2025,
Ascendis Pharma A/S - ADR (ASND) was held by
240 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
65,178,531 shares.
The largest 10 holders included
RA CAPITAL MANAGEMENT, L.P., WESTFIELD CAPITAL MANAGEMENT CO LP, Avoro Capital Advisors LLC, FMR LLC, JANUS HENDERSON GROUP PLC, Artisan Partners Limited Partnership, T. Rowe Price Investment Management, Inc., Capital International Investors, PRICE T ROWE ASSOCIATES INC /MD/, and MORGAN STANLEY.
This page lists
242
institutional shareholders reporting positions in this security
for the Q1 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.